United Kingdom: These 3 Drugs Face Patent Expirations and Generic Entry in 2026 - 2027

Generic name: beclomethasone dipropionate
DrugPatentWatch^® Estimated Patent Expiration / Generic Entry Opportunity Date: April 11, 2027
Generic Entry Controlled by: United Kingdom Patent 706,999

QVAR REDIHALER is a drug marketed by Norton Waterford. There are seventeen patents protecting this drug. One tentatively approved generic is ready to enter the market.

This drug has two hundred and seventy-eight patent family members in twenty-seven countries. There has been litigation on patents covering QVAR REDIHALER

See drug price trends for QVAR REDIHALER.

The generic ingredient in QVAR REDIHALER is beclomethasone dipropionate. There are twenty drug master file entries for this API. Two suppliers are listed for this generic product. Additional details are available on the beclomethasone dipropionate profile page.

Generic name: deoxycholic acid
DrugPatentWatch^® Estimated Patent Expiration / Generic Entry Opportunity Date: June 19, 2027
Generic Entry Controlled by: United Kingdom Patent 912,493

KYBELLA is a drug marketed by Abbvie. There are sixteen patents protecting this drug and one Paragraph IV challenge.

This drug has one hundred and forty-seven patent family members in thirty-eight countries. There has been litigation on patents covering KYBELLA

The generic ingredient in KYBELLA is deoxycholic acid. There are thirty-three drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the deoxycholic acid profile page.

Generic name: aliskiren hemifumarate; hydrochlorothiazide
DrugPatentWatch^® Estimated Patent Expiration / Generic Entry Opportunity Date: June 23, 2026
Generic Entry Controlled by: United Kingdom Patent 612,540

TEKTURNA HCT is a drug marketed by Noden Pharma. There is one patent protecting this drug and one Paragraph IV challenge.

This drug has thirty-two patent family members in twenty-five countries. There has been litigation on patents covering TEKTURNA HCT

See drug price trends for TEKTURNA HCT.

The generic ingredient in TEKTURNA HCT is aliskiren hemifumarate; hydrochlorothiazide. There are four drug master file entries for this API. Additional details are available on the aliskiren hemifumarate; hydrochlorothiazide profile page.

Generic name: technetium tc-99m tetrofosmin kit
DrugPatentWatch^® Estimated Patent Expiration / Generic Entry Opportunity Date: September 21, 2027
Generic Entry Controlled by: United Kingdom Patent 718,386

MYOVIEW 30ML is a drug marketed by Medi-physics. There is one patent protecting this drug.

This drug has eight patent family members in seven countries.

The generic ingredient in MYOVIEW 30ML is technetium tc-99m tetrofosmin kit. There are four drug master file entries for this API. Additional details are available on the technetium tc-99m tetrofosmin kit profile page.

Generic name: remimazolam besylate
DrugPatentWatch^® Estimated Patent Expiration / Generic Entry Opportunity Date: July 10, 2026
Generic Entry Controlled by: United Kingdom Patent 613,692

BYFAVO is a drug marketed by Acacia. There are eleven patents protecting this drug.

This drug has fifty-three patent family members in twenty-four countries. There has been litigation on patents covering BYFAVO

See drug price trends for BYFAVO.

The generic ingredient in BYFAVO is remimazolam besylate. One supplier is listed for this generic product. Additional details are available on the remimazolam besylate profile page.

Generic name: remimazolam besylate
DrugPatentWatch^® Estimated Patent Expiration / Generic Entry Opportunity Date: July 10, 2026
Generic Entry Controlled by: United Kingdom Patent 613,694

BYFAVO is a drug marketed by Acacia. There are eleven patents protecting this drug.

This drug has fifty-three patent family members in twenty-four countries. There has been litigation on patents covering BYFAVO

See drug price trends for BYFAVO.

The generic ingredient in BYFAVO is remimazolam besylate. One supplier is listed for this generic product. Additional details are available on the remimazolam besylate profile page.

Generic name: macimorelin acetate
DrugPatentWatch^® Estimated Patent Expiration / Generic Entry Opportunity Date: February 18, 2026
Generic Entry Controlled by: United Kingdom Patent 603,295

MACRILEN is a drug marketed by Novo. There is one patent protecting this drug.

This drug has eleven patent family members in ten countries.

See drug price trends for MACRILEN.

The generic ingredient in MACRILEN is macimorelin acetate. One supplier is listed for this generic product. Additional details are available on the macimorelin acetate profile page.